GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » EV-to-EBITDA

Theratechnologies (Theratechnologies) EV-to-EBITDA : -20.20 (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Theratechnologies's enterprise value is $80.28 Mil. Theratechnologies's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 was $-3.98 Mil. Therefore, Theratechnologies's EV-to-EBITDA for today is -20.20.

The historical rank and industry rank for Theratechnologies's EV-to-EBITDA or its related term are showing as below:

THTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22887.82   Med: -7.52   Max: 633.78
Current: -20.54

During the past 13 years, the highest EV-to-EBITDA of Theratechnologies was 633.78. The lowest was -22887.82. And the median was -7.52.

THTX's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs THTX: -20.54

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Theratechnologies's stock price is $1.28. Theratechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.560. Therefore, Theratechnologies's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Theratechnologies EV-to-EBITDA Historical Data

The historical data trend for Theratechnologies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies EV-to-EBITDA Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21,721.40 -24.10 -19.42 -8.78 -9.20

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.52 -5.56 -3.80 -9.20 -22.42

Competitive Comparison of Theratechnologies's EV-to-EBITDA

For the Biotechnology subindustry, Theratechnologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Theratechnologies's EV-to-EBITDA falls into.



Theratechnologies EV-to-EBITDA Calculation

Theratechnologies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=80.282/-3.975
=-20.20

Theratechnologies's current Enterprise Value is $80.28 Mil.
Theratechnologies's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies  (NAS:THTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Theratechnologies's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.28/-0.560
=At Loss

Theratechnologies's share price for today is $1.28.
Theratechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.560.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Theratechnologies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Theratechnologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (Theratechnologies) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.